|
|
 |
|
Viewing report
|
|
|
|
Switzerland Pharmaceuticals and Healthcare Report Q2 2010
Business Monitor International, March 2010, Pages: 75
Switzerland Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Switzerland's pharmaceuticals and healthcare industry.
In BMI’s Business Environment Ratings for Q210, Switzerland remains placed second, having lost its pole position to Germany in Q409. Globally, the country is no longer within the top five, now placing 6th, between Australia and Belgium, out of the 71 markets surveyed in our pharmaceutical universe. Switzerland may fall further down the world ranking as large, high-growth emerging markets such as Brazil and China become more alluring to multinational drugmakers in the medium to longer term. Switerland’s drug market was valued at CHF5.9bn (US$5.5bn) in 2008, with this figure rising to CHF6.1bn (US$5.6bn) in 2009, despite the flat performance of the over-the-counter (OTC) segment. According to IMS figures, the market rose by 3.4% in value in 2009, reaching CHF4.9bn at exmanufacturers’ prices. The rate of increase was slower than in previous years (some 5.5% in 2008), as the higher uptake of generics played a major role in market development. In fact, hospital-used generics increased by 3.9% y-o-y in value to CHF449mn in 2009. Through to 2014, we forecast that the value of the Swiss pharmaceutical market will post a compound annual growth rate (CAGR) of 2.00% in local currency, reaching CHF6.7bn (US$5.4bn), with the following five years proving to be even more challenging.
In the meantime, the Swiss government recently approved an amendment to the law regulating the dispensing and authorisation of medicines in Switzerland (Heilmittelgesetz). A hearing is currently in progress, with the outcome potentially to ban doctors from dispensing medicines in their surgeries. Presently, across 17 of the 26 Swiss cantons, this practice of self-dispensation is partly or wholly permitted, though it is already banned in the remaining nine. The new legislation also envisages a lowering of the profit margin from the current 15% to 12%, which would clearly have an impact on the performance of the prescription segment. On a positive note, the changes would be welcomed by the country’s retail pharmacy industry, as it would significantly reduce competition.
In terms of major industry news, US-based Cephalon is poised to acquire Swiss generic drugmaker Mepha AG and its subsidiaries from the family of the late German billionaire Adolf Merckle, for US$590mn. French Sanofi-Aventis, through its Winthrop generics arm (which has a limited presence in Switzerland), had previously been linked with the purchase of Mepha. While the company commands the largest share of the Swiss generic medicines market – alongside Novartis’s Sandoz – Mepha is also focused on creating improved and innovative medicine dosage formulations and on the marketing of branded and non-branded generic drugs. Generally speaking, however, the Swiss generics market is considered relatively unattractive to foreign players compared with its Western European counterparts. The Mepha-Sandoz duopoly has been highlighted as the key reason for this situation, despite considerable growth in both volume and value terms in the generics market in recent years, as well as a positive longer-term outlook for the segment, which is forecast to account for over 12% of the total market by 2014, up from less than 10% presently.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Switzerland Pharmaceuticals and Healthcare Report Q1 2011
Switzerland Pharmaceuticals and Healthcare Report Q1 2011
Switzerland Pharmaceuticals and Healthcare Report Q1 2011
Switzerland Pharmaceuticals and Healthcare Report Q1 2011
Switzerland Pharmaceuticals and Healthcare Report Q1 2011
Switzerland Pharmaceuticals and Healthcare Report Q1 2011
Switzerland Pharmaceuticals and Healthcare Report Q3 2011
Switzerland Pharmaceuticals and Healthcare Report Q4 2010
Serbia Pharmaceuticals and Healthcare Report Q1 2011
Kazakhstan Pharmaceuticals and Healthcare Report Q1 2011
|
|
|
|
